Macquarie Group Ltd. bought a new position in Intrexon Corp. (NYSE:XON) during the second quarter, Holdings Channel reports. The institutional investor bought 27,601 shares of the company’s stock, valued at approximately $679,000.
A number of other hedge funds have also recently added to or reduced their stakes in XON. Metropolitan Life Insurance Co. NY increased its stake in Intrexon Corp. by 13.7% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,161 shares of the company’s stock worth $102,000 after buying an additional 501 shares in the last quarter. Pacer Advisors Inc. bought a new position in shares of Intrexon Corp. during the second quarter valued at $118,000. Advisor Group Inc. bought a new position in shares of Intrexon Corp. during the second quarter valued at $123,000. Legal & General Group Plc boosted its position in shares of Intrexon Corp. by 3.4% in the first quarter. Legal & General Group Plc now owns 3,788 shares of the company’s stock valued at $128,000 after buying an additional 126 shares during the period. Finally, BlackRock Inc. boosted its position in shares of Intrexon Corp. by 17.1% in the second quarter. BlackRock Inc. now owns 6,766 shares of the company’s stock valued at $166,000 after buying an additional 986 shares during the period. 84.05% of the stock is owned by institutional investors and hedge funds.
Shares of Intrexon Corp. (NYSE:XON) opened at 27.19 on Tuesday. Intrexon Corp. has a 1-year low of $18.52 and a 1-year high of $43.76. The company’s 50-day moving average price is $27.31 and its 200 day moving average price is $28.48. The company’s market cap is $3.22 billion.
Intrexon Corp. (NYSE:XON) last released its quarterly earnings results on Tuesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.16. The firm had revenue of $52.50 million for the quarter, compared to the consensus estimate of $53.78 million. Intrexon Corp. had a negative net margin of 96.65% and a negative return on equity of 19.00%. Intrexon Corp.’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.37) earnings per share. On average, analysts predict that Intrexon Corp. will post ($1.36) earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the company. Griffin Securities reiterated a “buy” rating and issued a $65.00 price target on shares of Intrexon Corp. in a research report on Tuesday, June 7th. Wunderlich reiterated a “buy” rating and issued a $50.00 price target on shares of Intrexon Corp. in a research report on Thursday, July 7th. Stifel Nicolaus reiterated a “buy” rating and issued a $57.00 price target on shares of Intrexon Corp. in a research report on Wednesday, June 29th. Zacks Investment Research upgraded Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 price target for the company in a research report on Tuesday, July 19th. Finally, JMP Securities reiterated a “buy” rating on shares of Intrexon Corp. in a research report on Sunday, July 17th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $41.71.
In other news, SVP Nir Nimrodi purchased 4,000 shares of the stock in a transaction dated Monday, August 29th. The shares were purchased at an average cost of $26.12 per share, with a total value of $104,480.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 55.10% of the company’s stock.
Intrexon Corp. Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp. (NYSE:XON).
Receive News & Ratings for Intrexon Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp. and related companies with MarketBeat.com's FREE daily email newsletter.